CNS Pharmaceuticals (NASDAQ:CNSP) Stock Price Up 3.3% – What’s Next?

Shares of CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) traded up 3.3% during mid-day trading on Tuesday . The company traded as high as $7.51 and last traded at $7.27. 31,185 shares traded hands during trading, a decline of 55% from the average session volume of 69,541 shares. The stock had previously closed at $7.04.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of CNS Pharmaceuticals in a research report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, CNS Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $20.00.

CNS Pharmaceuticals Stock Performance

The stock has a market cap of $4.51 million, a price-to-earnings ratio of -0.23 and a beta of 2.69. The company’s 50 day simple moving average is $6.51 and its two-hundred day simple moving average is $7.51.

CNS Pharmaceuticals (NASDAQ:CNSP) last posted its quarterly earnings results on Friday, November 14th. The company reported ($5.76) EPS for the quarter, beating the consensus estimate of ($6.63) by $0.87.

Institutional Investors Weigh In On CNS Pharmaceuticals

An institutional investor recently bought a new position in CNS Pharmaceuticals stock. Armistice Capital LLC acquired a new stake in shares of CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 406,000 shares of the company’s stock, valued at approximately $335,000. Armistice Capital LLC owned approximately 90.22% of CNS Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 14.02% of the company’s stock.

CNS Pharmaceuticals Company Profile

CNS Pharmaceuticals, Inc, headquartered in Houston, Texas, is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive central nervous system tumors. The company’s lead candidate, berubicin, is an anthracycline derivative engineered to cross the blood-brain barrier for the treatment of glioblastoma multiforme and other brain cancers. In addition to berubicin, CNS Pharmaceuticals is advancing WP1066, an immunotherapy agent designed to inhibit the STAT3 signaling pathway and enhance anti-tumor immune activity in the tumor microenvironment.

Berubicin has completed a Phase 1 clinical trial in patients with recurrent glioblastoma, where it demonstrated proof-of-concept signals, and is currently in Phase 2 development.